Akebia Therapeutics, Inc. (AKBA)

NASDAQ: AKBA · USD

$0.78

+0.11 (+17.4%)· Recorded snapshot

Market cap	214.8M
Revenue (ttm)	219.1M
Net income (ttm)	-29.7M
EPS (ttm)	-$0.11
Shares out	277.1M
Volume	6,658,590
Beta	0.18

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 219.1M
Net income (ttm): -29.7M
EPS (ttm): -$0.11
Market cap: 214.8M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	持有

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-109.4

P25 n/aP50 n/aP75 n/a

ROIC-1.6

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All AKBA indicators

Market & fundamental data

Available fields

223

Groups with data

Currency

USD

Showing 223 of 223 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001517022
Company name	Akebia Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	00972D105
Earnings date	2026-11-09
Earnings time	bmo
Employees	194
Employees change	13
Employees growth	7.18%
Enterprise value	$258.4M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2007
In index	RUSSELL2000
Industry	Drug Manufacturers - Specialty & Generic
IPO date	2014-03-20
Is primary listing	Yes
Is SPAC	No
ISIN number	US00972D1054
Last 10-K release date	2026-02-26
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$214.8M
Market cap category	Micro-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$0.78
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	AKBA
U.S. state	Massachusetts
Website	https://www.akebia.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-14.35%
EV/FCF	6.06x
EV/Sales	1.11x
FCF / EV yield	16.5%
FCF yield	20.1%
Forward EV/Sales	1.57x
Forward P/S	1.29x
Industry forward P/E	13.87x
Industry P/E	173.94x
P/(FCF - SBC) ratio	7.43x
P/(OCF - SBC) ratio	7.09x
P/B ratio	7.17x
P/FCF ratio	4.98x
P/OCF ratio	4.82x
P/S ratio	0.91x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-2.67%
EBITDA margin	-1.96%
FCF margin	18.38%
Gross margin	81.44%
Operating margin	-2.67%
Pretax margin	-12.71%
Profit margin	-13.54%
Profit per employee	$-152,918
Revenue per employee	$1.1M
ROA	-1.05%
ROA (5Y)	-9.1%
ROCE	-3.1%
ROE	-109.38%
ROIC	-1.63%
SBC / revenue	6.08%
Tax / revenue	0.83%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	1
FCF growth (Q)	-88.99%
Gross profit growth	5.19%
Gross profit growth (Q)	-23.44%
Gross profit growth 3Y	-2.37%
Gross profit growth 5Y	5.28%
Net income growth years	1
OCF growth (Q)	-84.23%
Revenue growth	7.52%
Revenue growth (Q)	-21.36%
Revenue growth (QoQ)	-8.25%
Revenue growth 3Y	2.93%
Revenue growth 5Y	-0.26%
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-1.3M
Depreciation and amortization	$1.6M
EBIT	$-5.8M
EBITDA	$-4.3M
EPS	$-0.11
FCF per share	$0.15
Financing cash flow	$-11.2M
Free cash flow	$40.3M
Free cash flow minus SBC	$27M
Gross profit	$178.4M
Income taxes	$1.8M
Investing cash flow	$-12.1M
Net borrowing	$-5.9M
Net cash flow	$18.3M
Net income	$-29.7M
Operating cash flow minus SBC	$28.2M
Operating income	$-5.8M
Revenue	$219.1M
Stock-based compensation	$13.3M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-5.02
Book value per share	$0.09
Debt / EBITDA	220.34
Debt / equity	7.96
Debt / FCF	4.95
Goodwill	$59M
Interest coverage	-0.34
Long-term assets	$120.1M
Long-term liabilities	$163.8M
Net cash (debt)	$-43.6M
Net cash / market cap	-21.78%
Net debt / equity	1.74
Net debt / FCF	1.08
Piotroski F-Score	3
Property, plant and equipment	$7.3M
Shareholders' equity	$25M
Tangible book value	$-34M
Tangible book value per share	$-0.13
Total assets	$349.7M
Total cash	$155.5M
Total debt	$199.2M
Total liabilities	$324.6M
WACC	6.06%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.63
Current assets	$229.6M
Current liabilities	$160.9M
Current ratio	1.43
Inventory turnover	2.74
Net working capital	$-48.9M
Quick ratio	1.3
Working capital	$68.7M
Working capital turnover	2.37

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-15.07%
Dividend yield	0%
Shareholder yield	-15.07%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-89.84%
10Y return CAGR	-20.44%
10Y total return	-89.84%
150-day SMA	$1.09
1D price change	17.37%
1M price change	-13.51%
1M total return	-13.51%
1W price change	32.43%
1W total return	32.43%
1Y price change	-75.55%
1Y return CAGR	-75.57%
1Y total return	-75.55%
20-day SMA	$0.74
200-day SMA	$1.15
3M price change	-39.45%
3M total return	-39.45%
3Y price change	-7.74%
3Y return CAGR	-2.65%
3Y total return	-7.74%
50-day SMA	$0.85
50-day SMA vs 200-day SMA	50under200
52-week high	$3.20
52-week high date	2025-10-28
52-week low	$0.54
52-week low date	2026-10-22
5Y price change	-71.19%
5Y return CAGR	-22.03%
5Y total return	-71.19%
6M price change	-45.42%
6M total return	-45.42%
All-time high	$31.00
All-time high date	2014-06-20
All-time low	$0.24
All-time low date	2022-10-24
Average true range (ATR)	$0.06
Average volume	8.9M
Beta (1Y)	0.08
Beta (2Y)	0.61
Beta (5Y)	0.18
Change from 52-week high	-75.78%
Change from 52-week low	42.98%
Change from all-time high	-97.5%
Change from all-time low	221.62%
Change from open	17.8%
Day's gap	-0.36%
Dollar volume	$5.2M
High price	$0.78
Low price	$0.66
Monthly RSI	37.71
Open price	$0.66
Position in 52-week range	100%
Premarket change	2.97%
Premarket close	$0.66
Premarket price	$0.68
Premarket volume	2.5K
Previous close	$0.66
Price vs 150-day SMA	-28.56%
Price vs 20-day SMA	5.21%
Price vs 200-day SMA	-32.83%
Price vs 50-day SMA	-9.19%
Relative volume	0.75
RSI	51.95
Sharpe ratio	-1.33
Sharpe ratio (3Y)	0.32
Sharpe ratio (5Y)	0.18
Sortino ratio	-1.56
Sortino ratio (3Y)	0.53
Sortino ratio (5Y)	0.32
Volume	6.7M
Weekly RSI	39.73
YTD price change	-51.86%
YTD total return	-51.86%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	272.3M
Float percentage	98.25%
Shares change (QoQ)	0.96%
Shares change (YoY)	15.07%
Shares held by insiders	1.75%
Shares held by institutions	41.26%
Shares outstanding	277.1M
Short % of float	8.26%
Short % of shares	8.11%
Short ratio	3.1 days

Deeper analysis on AKBA

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this AKBA report

Is a complete AKBA research report available?

No complete published report is available for Akebia Therapeutics, Inc. (AKBA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Akebia Therapeutics, Inc. (AKBA)

Price

Financial snapshot

Fair-value bridge

Latest news · AKBA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All AKBA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on AKBA

Frequently asked questions